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Two-pore domain potassium (K2P) channels are expressed in cells 
throughout the body and give rise to leak potassium currents 
which control the excitability of these cells. Although not inhibited 
by classical potassium channel-blocking drugs, such as 
tetraethylammonium and 4-aminopyridine, K2P channels are 
regulated by a diverse array of pharmacological mediators. There 
are six main families of K2P channels and among these certain 
members of the TREK family (ie, TREK-1 and TREK-2) are 
activated by general anesthetic agents such as halothane, xenon 
and nitrous oxide. In addition, all members of the TREK family  
are activated by neuroprotective agents, such as riluzole, 
polyunsaturated fatty acids and lysophospholipids, suggesting that 
these channels play an important role in neuroprotection. TREK 
channels are also inhibited by chlorpromazine, local anesthetics 
and the antidepressant fluoxetine. Furthermore, all members of the 
TASK family are inhibited by cannabinoids and local anesthetics, 
and TASK-3 is selectively inhibited by ruthenium red. Thus, the 
diversity and physiological importance of K2P channels suggest 
that the development of selective compounds to target these 
proteins has therapeutic potential for CNS disorders such as 
stroke, depression and epilepsy.  
 
Keywords Antidepressant, cannabinoid, ciclosporin, 
fluoxetine, general anesthetic, lysophospholipid, neuro-
protection, polyunsaturated fatty acid, ruthenium red, two-
pore domain potassium channel 
Introduction 
Two-pore domain potassium (K2P) channels give rise to leak 
potassium currents and are expressed throughout the CNS 
[1,2] and in most other organs in the body [3•,4•,5•]. They 
contribute to the resting membrane potential of neurons and 
regulate their excitability. While K2P channels are generally 
open at all voltages, they also display some voltage 
dependency [6]. There are 15 members of the human K2P 
channel superfamily, which can be divided into six main 
families based on their structural and functional properties: 
TREK, TASK, TWIK, TALK, THIK and TRESK (Figure 1) 
[3•,4•,7-9]. Furthermore, K2P channels are regulated  
by a diverse array of pharmacological agents,  
physiological mediators and neurotransmitter-activated 
pathways [3•,5•,7].  
 
Currently, there are no compounds specifically designed to 
inhibit K2P channels; however, a large number of existing 
compounds act on these channels to alter their activity. In 
some instances, the action of these compounds may underlie 
or contribute to their therapeutic activity. The physiological 
consequences of such activity may lead to the generation of 
compounds that selectively inhibit K2P channels for a 
particular therapeutic advantage. K2P channels can also be 
regulated indirectly (ie, by G-protein-coupled receptor 
pathways and kinases), and thus compounds which interact 
with these indirect pathways also have important 
physiological actions mediated via K2P channels. However, 
it is beyond the scope of this review to also consider these 
indirect regulatory pathways (see reference [10] for 
examples). This review focuses on compounds that directly 
modulate K2P channel activity, assesses the physiological 
consequences of such actions and discusses whether these 
(or any related, more selective, second-generation) 
compounds provide further support for the potential 
targeting of K2P channels in CNS diseases such as stroke, 
epilepsy and depression. 
General blockers of K2P channels 
An interesting pharmacological feature of K2P channels is 
that they are highly insensitive to both of the classical  
drugs used to block voltage-gated potassium channels: 
tetraethylammonium (TEA) ions and 4-aminopyridine  
(4-AP). However, K2P channels can be blocked by barium 
ions and, in some cases, by quinidine and quinine.  
Quinidine and quinine 
Quinidine, a stereoisomer of the naturally occurring product 
quinine, is used as a class I anti-arrythmic agent in the heart 
and affects many ion channels, including sodium, calcium 
and potassium channels. While quinidine blocks the TASK-1 
and TASK-3 K2P channels modestly (approximately 30% at 
100 μM) [11-13], its effects on TREK-1 channels are more 
varied. An early study of TREK-1 channels expressed in 
Xenopus oocytes showed that the channels were unaffected 
by either quinidine or quinine [14]. However, later research 
with COS cells (transformed monkey kidney fibroblasts) 
suggested that quinidine could block TREK-1 channels [15]. 
Similarly, both quinine and quinidine block TWIK-2 channels 
but only when recordings are made in physiological potassium 
solutions – no blockade has been observed in symmetrical 
potassium solutions [16]. These latter observations highlight 
the importance of understanding the pharmacology of K2P 
channels; the effectiveness of certain compounds is dependent 
upon the experimental approach, and certain compounds 
(presumably those that interact with the permeation pathway) 
are influenced by the concentration and the net direction of 
movement of the permeating ion. Of the other K2P channels, 
TRESK [17,18]  and TRAAK [19] are inhibited by both 
quinidine and quinine. However, the situation for TALK 
channels is more complicated. While both TALK-1 and 
TALK-2 channels are inhibited by quinidine (1 mM), quinine 
strongly inhibited TALK-1 channels and activated TALK-2 
channels [20,21].  
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The 15 members of the K2P channel superfamily are shown according to their six main groups. The K2P nomenclature as approved by the 
International Union of Basic and Clinical Pharmacology is shown in parentheses (see reference [4•] for further details). Note that the  
KCNK-7, THIK-2 and TASK-5 subtypes are functionally silent when expressed in isolation. 
 
It is generally useful for a compound to selectively act on 
either a particular K2P channel family or an individual 
family member. The most extensively researched families of 
K2P channels are the TREK and TASK families, and as such 
this review focuses on compounds in relation to these two 
families. However, where effects of compounds have also 
been observed in other K2P channel families these will also 
be mentioned.  
The TREK family of K2P channels 
The TREK family (TREK-1, TREK-2 and TRAAK) is the most 
widely studied of the K2P channels and appears to show the 
largest diversity of regulation by pharmacological agents 
[22]. A number of compounds have been identified which 
either upregulate or downregulate TREK channel activity, 
and among these several compounds have shown important 
therapeutic actions, for example, as general anesthetic and 
neuroprotective agents.  
General anesthetic agents 
General anesthetics can be divided into three broad classes: 
intravenous agents (such as barbiturates, propofol and 
etomidate), volatile anesthetics (such as halothane, 
chloroform and isoflurane) and gaseous anesthetics (such as 
xenon, nitrous oxide and cyclopropane). While intravenous 
agents appear to have little effect on K2P channels and likely 
mediate their anesthetic activity through enhancement of 
GABAA receptor activity, the volatile anesthetics have a 
range of stimulatory and inhibitory effects on K2P channels 
in addition to their actions on GABAA receptors [23••,24-26].  
 
TREK-1 and TREK-2 (but not TRAAK) channels are 
activated by general anesthetics [19,23••], and progressive 
deletion of the C terminus of TREK-1 suggests that this 
region is important for their anesthetic activity [23••]. In 
addition, the reduced sensitivity to volatile anesthetics in 
TREK-1 knockout animals [27••] suggests that the action of 
volatile anesthetics on TREK-1 channels is of considerable 
physiological importance. 
 
Interestingly, gaseous anesthetics appear to selectively target 
and enhance the activity of TREK-1 channels (and 
presumably the related TREK-2 channels) with little action 
on other K2P channels [26,28••]. The effect of these agents 
on TREK-1 activity was completely abolished by a single 
amino-acid point mutation (ie, E306A) in the C terminus of 
TREK-1 [28••], again confirming the importance of this 
region in transducing the effect of many regulatory 
compounds on TREK-1 [29•]. The activation of TREK-1 
channels by gaseous anesthetic agents may also contribute to 
their neuroprotective effects (see below and reference [26]). 
 
Trichloroethanol (TCE; a metabolic by-product of chloral 
hydrate and which is responsible for the pharmacological 
actions of chloral hydrate) has been shown to regulate TREK 
channels [30]. In addition, TCE (5 mM) activated both 
human (h)TREK-1 and hTRAAK channels [30]. This latter 
finding is particularly surprising because TRAAK channels, 
unlike other TREK and TASK family members, are 
insensitive to inhalation anesthetics and thus was the first 
indication that an anesthetic could have an effect on TRAAK 
channels.  
 
Arguably, general anesthetics are among the most 
'promiscuous' of all compounds which act on K2P channels. 
In addition to their action on TREK channels, certain general 
anesthetics also act on TASK channels to enhance their 
activity (see below for further information). Furthermore, 
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TRESK channels are extremely sensitive to volatile 
anesthetics such as isoflurane, halothane, sevoflurane and 
desflurane. While the effect is species dependent [31], 
hTRESK channels are more strongly enhanced by volatile 
anesthetics compared with other K2P channels [32]. As 
volatile anesthetics produce surgical immobility via a spinal 
cord-mediated function, this finding suggests a role for 
hTRESK channels in anesthetic mechanisms. On the other 
hand, a number of K2P channels are inhibited by general 
anesthetic agents, for example, halothane inhibits members 
of the TWIK and THIK families [16,25]. Furthermore, 
halothane demonstrates various actions on the TALK family, 
as it inhibits TALK-1 and TALK-2 [20], and activates TASK-2 
[33]. 
Neuroprotective agents 
A number of neuroprotective compounds regulate the 
activity of TREK channels, including riluzole (Rilutek) a 
potent neuroprotective drug used to treat amyotrophic 
lateral sclerosis [34]. In preclinical trials, riluzole 
demonstrated efficacy in preventing spinal cord injury and 
improving recovery from ischemia in the rat retina [35,36]. 
Riluzole (10 to 100 μM) enhanced the activity of both  
TREK-1 and TRAAK channels through a direct interaction 
with the specific channel [37•]. However, prolonged 
application of riluzole has a biphasic effect on TREK-1 
channels (but not TRAAK channels) with a secondary 
inhibition of current also observed. This is an indirect effect 
that occurs via the inhibitory action of cAMP on TREK-1 
channels, due to the blockade of PDE breakdown of cAMP 
by riluzole [37•]. It is not clear which of the two effects will 
dominate in vivo. Furthermore, sipatrigine (BW-619-C89; 
discontinued from development for the treatment of stroke 
by CeNeS Pharmaceuticals plc in 2002 [38]) demonstrated 
potent inhibition of TREK-1 and TRAAK channels in animal 
models of stroke [39]. Therefore, and somewhat 
surprisingly, some neuroprotective agents can both enhance 
and inhibit the activity of TREK and TRAAK channels. 
 
Polyunsaturated fatty acids (PUFAs), such as linoleic acid 
(found in high quantities in vegetable oils), have also 
demonstrated protection against neuronal ischemia [40]. 
Arachidonic acid (AA) and other PUFAs activate all three 
members of the TREK family [15,41,42]. This activation 
initially protects the neurons; however, high levels of AA 
can occur during seizures and in ischemia [43], resulting in 
neuronal cell death [44-46].  
 
A potent protective role of lysophospholipids has also been 
demonstrated in global cerebral ischemia and glutamate 
excitotoxicity in rats [26,47]. Lysophosphatidic acid (LPA) is a 
bioactive lipid with both extra- and intracellular targets, and 
important roles in physiology and pathophysiology. 
Lysophospholipids also activate TREK channels [19,48] and 
converts them into pure leak potassium conductances, with 
LPA demonstrating an EC50 value of approximately 2.5 μM 
[49•].  
 
Because PUFAs and extracellular lysophospholipids are 
neuroprotective and activate TREK and TRAAK channels, 
they appear to have an important physiological role  
in neuroprotection [40]. The role of the TREK-1 channel  
in PUFA- and LPA-induced neuroprotection was 
demonstrated by comparing TREK-1 wild-type mice with 
TREK-1 knockout mice [27••]. Importantly, PUFA- and 
LPA-induced neuroprotection was not observed in the 
TREK-1 knockout mice. In addition, the combined effect of 
riluzole and linoleic acid post-ischemia has demonstrated 
beneficial effects to both individual neuron survival and 
overall animal survival [50].  
 
At a molecular level, the effects of neuroprotective agents 
are dependent upon an intracellular glutamate residue at 
position 306 (E306), which acts as a key sensor for 
transduction (similarly to general anesthetics). What is not 
clear, however, is where on the channels these 
neuroprotectants bind or whether there are multiple binding 
sites for the different activators of TREK channels. Indeed, 
the effect of LPA (but not PUFAs) has been suggested to be 
mediated through a change in the curvature of the 
membrane [49•], rather than direct binding to the channel 
itself. 
Antipsychotic and antidepressant agents  
TREK channels are inhibited by the antipsychotic agent 
chlorpromazine [14] and the antidepressant fluoxetine  
(IC50 = 19 μM, or 9 μM for norfluoxetine) [51]. Fluoxetine 
blockade of TREK-1 channels does not require the  
C terminus of the channel (in contrast to the activation 
observed with the general anesthetics and AA [23••,28••]); 
however, it appears to interact with the transduction 
pathway through E306, and thus acts as an allosteric blocker 
of channel activity [28••,51]. Both chlorpromazine and 
fluoxetine are lipophilic and it has been suggested that they 
enter the lipid membrane and act as a cationic amphipath to 
change the curvature of the membrane and inhibit TREK-1 
channel current [15]. In other words, chlorpromazine may 
act in the opposite manner to LPA (which enhances current). 
It was originally thought that neither chlorpromazine nor 
fluoxetine produced their effects through an interaction with 
TREK channels, and that their actions may contribute to 
some of the side effects observed, such as an exacerbation of 
convulsion tendency. However, a recent study using TREK-1 
knockout mice reported that these animals displayed an 
antidepressant phenotype, suggesting that the action of 
fluoxetine and other antidepressant agents on TREK-1 
channels may contribute, at least in part, to their therapeutic 
benefit in the treatment of depression [52••]. 
Local anesthetic agents 
A number of amide-linked local anesthetic agents (such as 
lidocaine, mepivacaine [AP Pharma Inc; Figure 2], 
tetracaine, rupivacaine and bupivacaine) inhibit various K2P 
channels, with little or no effect occurring with ester-linked 
local anesthetics [53,54]. The increase in membrane 
excitability following K2P channel blockade may contribute 
to the cardiotoxic and excitotoxic side effects of local 
anesthetics. For example, bupivacaine, in comparison with 
other local anesthetics, is markedly cardiotoxic and inhibits 
TREK-1, TASK-1 and TASK-2 channels [53,54] – all of which 
are highly expressed in the heart and CNS. Another possible 
K2P channel-related side effect of local anesthetics is 
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tinnitus, as a number of local anesthetic-sensitive K2P 
channels are highly expressed in the cochlea [55]. Similar to 
general anesthetic agents, local anesthetics demonstrate 
activity on a number of other K2P channels, and in all cases 
these actions have also been inhibitory [31,53,54].  
Other agents that act on TREK channels 
A number of other therapeutically important agents have 
demonstrated activity on the TREK family of K2P channels, 
including theophylline [56], caffeic acid derivatives [57•], 
flufenamic acid [58,59], diltiazem [59] and mibefradil 
[49•,60]. 
Theophylline 
Theophylline and caffeine belong to the family of xanthine 
alkaloids, which are used therapeutically as bronchodilators 
and mild stimulants. It has been suggested that the 
epileptogenicity of excess caffeine and theophylline may be 
related to their inhibition of K2P channels, in particular the 
TREK-1 channels [56].  
Caffeic acid derivatives 
Caffeic acid is a carboxylic acid found in many fruits, vegetables 
and beverages (including coffee, although there is no other 
connection between caffeic acid and caffeine). Certain caffeic 
acid derivatives (such as cinnamyl 1-3,4-dihydroxy-a-
cyanocinnamate; 5 to 10 μM) markedly enhance the activity of 
TREK-1 channels [57•], although caffeic acid itself is without 
effect. It appears that caffeic acid derivatives bind to an external 
site to produce their effects on TREK-1 channels [57•] in 
contrast with other agents that act via an intracellular site  
(ie, AA). 
Flufenamic acid 
Fenamates belong to the family of NSAIDs, and demonstrate 
analgesic, antipyretic and anti-inflammatory properties. 
Fenamates stimulate the activity of a large conductance 
potassium channel in the rabbit and bovine corneal epithelium 
[58,59]. Importantly, this potassium channel was characterized 
as a mechano-gated K2P channel belonging to the 
TREK/TRAAK family. A number of fenamates, such as 
flufenamic acid, nifluemic acid and mefenamic acid (all at  
100 μM), were tested on recombinant members of the 
TREK/TRAAK family of channels [61]. As was observed in the 
corneal epithelium, fenamates augmented TREK-1, TREK-2 and 
TRAAK channel currents, which may contribute to their pain-
relieving and anti-inflammatory properties. 
Diltiazem and mibefradil 
The L-type calcium channel blocker diltiazem [59] and the  
T-type calcium channel blocker mibefradil [49•,60] inhibit 
members of the TREK family. In addition, diltiazem inhibits 
the background potassium conductance in the corneal 
epithelium. When administered to recombinant clones, 
diltiazem inhibited TREK-1 and TREK-2 channels (with a 
complete blockade at 1 mM), but had no effect on TRAAK 
channels [59].  
The TASK family of K2P channels 
The TASK family of K2P channels (including TASK-1, 
TASK-3 and the non-functional TASK-5) underlie leak 
potassium conductances in many CNS neurons. These 
channels are regulated by a number of signaling pathways 
in the neurons and by various pharmacological mediators, 
although there is currently a distinct lack of compounds that 
are selective for a particular channel type. 
Ruthenium red and zinc 
Ruthenium red inhibits a number of different channels and, 
as such, is not considered to be a selective antagonist for a 
particular K2P channel. Nevertheless, it has demonstrated 
selective inhibition of TASK-3 channels (IC50 = 0.7 μM) 
compared with TASK-1 and the heterodimeric TASK-1/ 
TASK-3 channels [62••]. As such, ruthenium red is useful as 
a diagnostic tool to distinguish between TASK channel types 
once it has been established that a TASK channel underlies 
the observed current. Interestingly, identification of the 
ruthenium red-binding region on the TASK-3 channel 
highlights the possibility of selectively targeting this site 
through rational drug design. Ruthenium red binds to a 
glutamate residue (E70) on the M1/P1 loop of TASK-3 (the 
large extracellular loop between the first transmembrane 
domain and the first pore region). The equivalent residue at 
position 70 is a lysine (potassium) in TASK-1 channels 
[62••]. The presence of the same residue also explains the 
relative selectivity of zinc for TASK-3 over TASK-1 (IC50  
= 20 μM) [63] and the ability of other divalent (ie, 
magnesium and calcium) and polyvalent (spermine) cations 
to specifically block TASK-3 channels [64]. Interestingly, 
heterodimeric TASK-1/TASK-3 channels are insensitive to 
ruthenium red, suggesting that two E residues at the E70 
position are required per channel for effective binding of the 
compound [62••]. These data support the M1/P1 loop as a 
potential site of action for the design of compounds which 
selectively act on particular TASK channel subtypes. 
Cannabinoids 
Anandamide (Yissum Research Development Co of the 
Hebrew University of Jerusalem/Kadmus Pharmaceuticals Inc; 
Figure 3) is a naturally occurring endogenous cannabinoid 
neurotransmitter found in the brain and other organs of the 
body, which binds to and activates the CB1 and CB2 
cannabinoid receptors. Anandamide and other cannabinoid 
agonists reproduce the effects of the psychoactive component of 
cannabis, Δ9-tetrahydrocannabinol. Endocannabinoid agonists, 
including anandamide, methanandamide and WIN-55212-2  
(R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo-
[1,2,3,-de]-1,4-benzoxazinyl]-(1-naphtalenyl)methanone 
mesylate), significantly inhibit TASK-1 channels [65] with little 
effect on other K2P channels. In addition, methanandamide 
is equally effective at blocking TASK-3 channels [2,66]. 
While WIN-55212-2 was being developed as a potential 
treatment for emesis, pain and inflammation by Sanofi 
Winthrop Inc [67], no development has been reported on 
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(Yissum Research Development Co of the Hebrew 
University of Jerusalem/Kadmus Pharmaceuticals)  
 
 
this compound since 1996 and it is now assumed to be used 
as a research tool. The effect of cannabinoids on  
TASK-1 and TASK-3 channels occurs independently of the 
cannabinoid receptors [65], and direct inhibition of these 
channels may explain some of the physiological and 
behavioral effects observed with these agonists, such as 
hypothermia, hypokinesia, analgesia and catalepsy. In 
support of this hypothesis, the analgesic, sedative and 
hypothermic effects of WIN-55212-2 were reduced in TASK-1 
knockout mice [68]. 
General anesthetic agents 
Halothane and isoflurane were originally considered potent 
activators for a variety of TASK family members 
[23••,69,70], and this effect was particularly strong in 
brainstem motoneurons and thalamocortical neurons [71,72] 
– the regions of the brain that are fundamentally important 
in mediating the loss of motor control and consciousness 
during general anesthesia. However, it has since been 
demonstrated that while high concentrations of isoflurane 
potentiate TASK-3 channels, TASK-1 channels are inhibited 
[73••]. Moreover, TASK-1/TASK-3 heterodimeric channels 
behave in a similar manner to TASK-3 channels as they are 
potentiated by isoflurane. Thus, together with other agents 
such as ruthenium red and zinc, isoflurane is particularly 
useful for discriminating between homodimeric and 
heterodimeric TASK channels in native neurons [2,73••]. 
Local anesthetic agents 
In addition to inhibiting TREK channels, local anesthetic 
agents are also inhibitors of TASK channels. Bupivacaine 
potently inhibits both TASK-1 and TASK-3 channels (IC50  
~ 40 μM) [11,12,53,54]. Lidocaine is approximately 5- to  
10-fold less effective than bupivacaine at inhibiting TASK-1 
and -3 channels (IC50 ~ 220 μM) [11,12].  
Other compounds which act on TASK channels 
Treprostinil  
Treprostinil is a stable analog of prostacyclin and is used to 
treat the symptoms of primary pulmonary hypertension 
[74]. This compound (IC50 = 1.2 μM) has demonstrated 
activation of TASK-1 channels present in pulmonary artery 
smooth-muscle cells via a protein kinase A-dependent 
pathway [75]. An important mechanism underlying the 
prostanoid-induced relaxation of pulmonary arteries might 
be elucidated from these data. 
Doxapram 
The analeptic agent doxapram, a respiratory stimulant used 
to treat ventilatory failure, inhibits TASK-1, TASK-3 and 
TASK-1/TASK-3 channels (EC50 = 410 nM, 37 μM and 9 μM, 
respectively) [76]. TASK-1 and TASK-3 channels are 
expressed in the carotid bodies and brainstem, and a 
potassium conductance with TASK-1-like properties has 
been identified in the carotid cell bodies [13]. Doxapram is 
known to stimulate chemoreceptors in the carotid bodies, 
suggesting that K2P channels (in particular TASK-1 
channels) have a role in chemosensing. 
Other blockers of K2P channels and native leak 
potassium channels 
Calcineurin inhibitors 
The most recently cloned member of the K2P channel 
superfamily, TRESK, was thought to be expressed solely in 
the spinal cord [17], but it has since been localized to various 
regions of the brain [32,77••] and dorsal root ganglia of mice 
[78]. One interesting property of TRESK channels is that they 
are activated in response to increased cytoplasmic calcium 
levels by the calcium/calmodulin-dependent protein 
phosphatase calcineurin [79]. A docking site similar to the 
NFAT (nuclear factor of activated T-cells) site has been 
identified on TRESK channels, suggesting that calcineurin 
may have a direct action on TRESK [77••]. In addition, 
common immunosuppressants, such as ciclosporin A  
(100 nM) and tacrolimus (200 nM), are specific inhibitors of 
calcineurin and have been shown to ablate TRESK channel 
activation [77••,79]. 
Ecstasy 
In cultured hippocampal neurons of rats, ecstasy  
(3,4-methylenedioxy-N-methylamphetamine [MDMA]) inhibits 
background potassium conductance (Figure 4), which leads 
to increased neuronal excitability and enhanced synaptic 
strength [80]. Hippocampal neurons express a large number 
of K2P channels to varying degrees [1], with TASK-3 and 
TREK-1 channels most highly expressed. It is not clear 
which K2P channels are the primary targets for MDMA; 
however, it has been suggested that this drug has no effect 
on recombinant TREK-1 and TASK-1 channels [7]. 
BL-1249 
BL-1249 (5,6,7,8-tetrahydro-naphthalen-1-yl)-2[-(1H-tetrazol-
5-yl)-phenyl]-amine is a putative activator of the potassium 
channels which are found in smooth-muscle cells of the 
bladder, and has demonstrated bladder-relaxant properties 
[81]. BL-1249 (EC50 = 1.5 μM) produced a concentration-
dependent membrane hyperpolarization, with a reversal 
potential of -80 mV, similar to the activation of potassium 
conductance [81]. This BL-1249-induced current was blocked 
by barium ions, and was insensitive to TEA and 4-AP, data 
characteristic of K2P channels. High levels of TREK-2 
mRNA were identified in human bladder myocytes using 
real-time PCR, and the kinetics and pharmacological 
properties of these channels correlated well with those of the 
BL-1249-evoked potassium currents [81]. 
Conclusion and future prospects 
K2P channels are expressed throughout the nervous system 
and have a role in controlling both the neuronal resting 
membrane potential and the degree of neuronal excitability. 
As such, they are prime targets for the potential treatment of 
many CNS disorders. In contrast to voltage-gated potassium 
channels, K2P channels are insensitive to TEA and 4-AP; 
however, they are blocked by barium ions and in many 
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(A) Inward whole-cell currents in hippocampal neurons were evoked 
by 3,4-methylenedioxy-N-methylamphetamine (MDMA) through the 
blockade of background potassium channels (all values in μM). (B) 
Single-channel recordings of background potassium currents in 
hippocampal neurons and their blockade by MDMA (50 μM).  
(Reproduced with permission from the American Society for 
Pharmacology and Experimental Therapeutics and Premkumar LS, 
Ahern GP: Blockade of a resting potassium channel and 
modulation of synaptic transmission by ecstasy in the 
hippocampus. J Pharmacol Exp Ther (1995) 274(2):718-722.  




cases by quinidine, quinine and local anesthetic agents. 
Thus, while it is possible to identify a current as carried 
through K2P channels, in most cases it is difficult to assess 
which K2P channel (or which family of K2P channels) 
underlies a particular current.  
 
The most commonly studied group of K2P channels are the 
TREK and TASK families, and there are a number of 
compounds which activate or inhibit these channels. 
Unfortunately, the large majority of these compounds have 
multiple actions on other channels and receptors. Therefore, 
while it is possible to identify the roles of individual K2P 
channels, there are currently no compounds available that 
are truly selective pharmacological agents. Nonetheless, for 
particular clinical issues, the regulation of K2P channel 
activity has important therapeutic applications. For example, 
considerable evidence suggests that TREK K2P channels are 
important for neuroprotection, and there is demonstrated 
potential for compounds which act to enhance their activity, 
such as riluzole [34], PUFAs (linoleic acid and AA [15,40-42]) 
and LPA [49•]. Similarly, recent studies on the effects of 
antidepressant agents on K2P channels and the creation of a 
TREK-1 knockout mouse with an antidepressant phenotype 
suggest that this channel is a good future target for the 
development of drugs for the treatment of depression 
[52••,82]. As such, continued research into the functional 
roles and physiological importance of K2P channels, 
together with the development of compounds that 
selectively target particular K2P channels, holds 
considerable therapeutic promise for CNS disorders.  
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